UA49799C2 - Циклопептиди, спосіб їх одержання, фармацевтична композиція, що їх містить, спосіб її одержання, спосіб боротьби з захворюваннями, спосіб одержання іммобілізованих лігандів - Google Patents

Циклопептиди, спосіб їх одержання, фармацевтична композиція, що їх містить, спосіб її одержання, спосіб боротьби з захворюваннями, спосіб одержання іммобілізованих лігандів

Info

Publication number
UA49799C2
UA49799C2 UA96093558A UA96093558A UA49799C2 UA 49799 C2 UA49799 C2 UA 49799C2 UA 96093558 A UA96093558 A UA 96093558A UA 96093558 A UA96093558 A UA 96093558A UA 49799 C2 UA49799 C2 UA 49799C2
Authority
UA
Ukraine
Prior art keywords
producing
cyclo
peptides
pharmaceutical composition
illness
Prior art date
Application number
UA96093558A
Other languages
English (en)
Russian (ru)
Inventor
Альфред ЙОНЦІК
Альфред ЙОНЦИК
Сімон Гудман
Симон ГУДМАН
Беате ДІФЕНБАХ
Беате Дифенбах
Арне ЗУТТЕР
Гюнтер ХЬОЛЬЗЕМАН
Хорст Кесслер
Міхель ДЕХАНТСРІТЕР
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of UA49799C2 publication Critical patent/UA49799C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Циклопептиди формули цикло-(nArg-nGly-nAsp-nD-nE), їх енантиоміри або диастереоміри, спосіб їх одержання, який полягає в тому, що сполуку виділяють у вільному вигляді із одного із його функціональних похідних обробкою сольволізуючим або гідрогенолізуючим засобом, фармацевтична композиція і спосіб її одержання, який полягає в тому, що ефективну кількість циклопептиду разом по крайній мірі із одним твердим, рідким або напіврідким носієм або допоміжною речовиною переводять в підходящу дозуючу форму, спосіб боротьби з захворюваннями, спосіб одержання іммобілізованих лігандів для колоночної афінної хроматографії, спосіб очищення інтегринів шляхом афінної хроматографії.
UA96093558A 1995-09-15 1996-09-13 Циклопептиди, спосіб їх одержання, фармацевтична композиція, що їх містить, спосіб її одержання, спосіб боротьби з захворюваннями, спосіб одержання іммобілізованих лігандів UA49799C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19534177A DE19534177A1 (de) 1995-09-15 1995-09-15 Cyclische Adhäsionsinhibitoren

Publications (1)

Publication Number Publication Date
UA49799C2 true UA49799C2 (uk) 2002-10-15

Family

ID=7772215

Family Applications (1)

Application Number Title Priority Date Filing Date
UA96093558A UA49799C2 (uk) 1995-09-15 1996-09-13 Циклопептиди, спосіб їх одержання, фармацевтична композиція, що їх містить, спосіб її одержання, спосіб боротьби з захворюваннями, спосіб одержання іммобілізованих лігандів

Country Status (29)

Country Link
US (1) US6001961A (uk)
EP (1) EP0770622B1 (uk)
JP (3) JP4115550B2 (uk)
KR (1) KR100438244B1 (uk)
CN (1) CN1203090C (uk)
AR (1) AR003574A1 (uk)
AT (1) ATE189461T1 (uk)
AU (1) AU717574B2 (uk)
BR (1) BR9603751A (uk)
CA (1) CA2185489C (uk)
CO (1) CO4750841A1 (uk)
CZ (1) CZ286713B6 (uk)
DE (2) DE19534177A1 (uk)
DK (1) DK0770622T3 (uk)
ES (1) ES2144179T3 (uk)
GR (1) GR3033293T3 (uk)
HU (1) HU224614B1 (uk)
ID (1) ID18770A (uk)
MX (1) MX9604100A (uk)
NO (1) NO316946B1 (uk)
PL (1) PL185125B1 (uk)
PT (1) PT770622E (uk)
RU (1) RU2157379C2 (uk)
SI (1) SI0770622T1 (uk)
SK (1) SK282391B6 (uk)
TR (1) TR199600716A2 (uk)
TW (1) TW517064B (uk)
UA (1) UA49799C2 (uk)
ZA (1) ZA967768B (uk)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US7053041B1 (en) 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
RU2195312C2 (ru) 1996-05-31 2002-12-27 Дзе Скриппс Рисерч Инститьют СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5-ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА
HUP9901628A3 (en) * 1996-05-31 2002-11-28 Scripps Research Inst Methods and compositions useful for inhibition of alfa v beta5 mediated angiogenesis
EP0917878A4 (en) * 1997-02-26 2004-05-19 Toray Industries REMEDIES FOR HEPATITIS
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
KR20010109275A (ko) 1998-12-23 2001-12-08 로저 에이. 윌리암스 종양치료의 병용치료로서 사이클로옥시게나제-2 억제제와기질 금속단백분해효소 억제제를 사용하는 방법
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
AU776790B2 (en) * 1999-02-12 2004-09-23 Lexigen Pharmaceuticals Corporation Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
ES2529706T3 (es) * 1999-06-01 2015-02-24 Biogen Idec Ma Inc. Un anticuerpo monoclonal bloqueante contra el dominio alfa1-I de VLA-1, y su uso para el tratamiento de trastornos inflamatorios
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
SI1381382T1 (sl) * 2000-11-01 2009-04-30 Merck Patent Gmbh Postopki in sestavki za zdravljenje oäśesnih bolezni
UA75898C2 (en) * 2000-11-14 2006-06-15 Merck Patent Gmbh Method for prophylaxis and treatment of eye diseases using antagonist of integrin receptors
EP1349574A2 (en) * 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
PL363311A1 (en) * 2001-04-24 2004-11-15 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and tnfalpha
PL371281A1 (en) * 2002-02-14 2005-06-13 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
WO2005017107A2 (en) 2003-07-18 2005-02-24 Amgen Inc. Specific binding agents to hepatocyte growth factor
DE10337863A1 (de) * 2003-08-18 2005-03-17 Merck Patent Gmbh Verwendung von Chromen-4-on-Derivaten
EP2348039A3 (en) * 2005-12-22 2011-08-24 Novabiotics Limited Cyclic antimicrobial peptides
US9181303B2 (en) 2005-12-22 2015-11-10 Novabiotics Limited Treatment of bacterial infections with cyclic antimicrobial peptides
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
ES2353482T3 (es) * 2006-02-10 2011-03-02 Amgen, Inc Formas hidrato de amg706.
CN105381459A (zh) * 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EA017864B1 (ru) 2007-01-18 2013-03-29 Мерк Патент Гмбх Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
US20090053280A1 (en) * 2007-05-15 2009-02-26 Michael Joner Coating stents with cyclic rgd peptides or mimetics
EP2167128B1 (en) 2007-07-17 2012-10-24 Merck Patent GmbH Engineered anti-alpha v- integrin hybrid antibodies
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
EP2259768B1 (en) 2008-04-08 2019-05-22 Merck Patent GmbH Compositions containing cyclic peptides and methods of use
PL2368118T3 (pl) 2008-12-23 2014-03-31 Merck Patent Gmbh Biomarkery dla inhibitorów z aktywnością antyangiogeniczną
CA2762652C (en) * 2009-05-20 2018-10-02 Merck Patent Gmbh Novel solid materials of {[(2s,5r,8s,11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
BR112012012862A2 (pt) 2009-12-10 2016-08-16 Merck Patent Gmbh composição farmacêutica compreendendo oligopeptídeos
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
CA2805338A1 (en) 2010-07-16 2012-01-19 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
US20130202652A1 (en) * 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2012069149A1 (en) 2010-11-23 2012-05-31 Merck Patent Gmbh Solution comprising cyclic oligopeptides
PT2672994T (pt) 2011-02-11 2018-10-22 Merck Patent Gmbh Anticorpo anti-integrina alfa-v para o tratamento do cancro da próstata
WO2012110200A1 (en) 2011-02-18 2012-08-23 Merck Patent Gmbh Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease
WO2012146729A1 (en) * 2011-04-29 2012-11-01 Philipps-Universität Marburg Lasso peptides as scaffolds for peptide grafting
ES2720477T3 (es) * 2011-06-09 2019-07-22 Merck Patent Gmbh Tratamiento de cánceres y metástasis con suspensiones de Cilengitide en portador
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US10160808B2 (en) 2012-02-16 2018-12-25 Santarus, Inc. Anti-VLA1 (CD49A) antibody pharmaceutical compositions
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
CA2961935C (en) 2013-09-24 2020-09-08 Hirofumi Fukunaga Nitrogen-containing compound or salt thereof, or metal complex thereof
DK3275883T3 (da) 2015-03-25 2021-06-28 Fujifilm Corp Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf
WO2017069627A1 (en) * 2015-10-23 2017-04-27 Universiteit Twente Integrin binding peptides and uses thereof
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
HUE056777T2 (hu) 2016-12-22 2022-03-28 Amgen Inc Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
UY37870A (es) 2017-09-08 2019-03-29 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3790886A1 (en) 2018-05-10 2021-03-17 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
WO2019232419A1 (en) 2018-06-01 2019-12-05 Amgen Inc. Kras g12c inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP2020090482A (ja) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
CA3123042A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
MA54543A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
CA3130083A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CA3140392A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
CN114269731A (zh) 2019-08-02 2022-04-01 美国安进公司 Kif18a抑制剂
WO2021026100A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Pyridine derivatives as kif18a inhibitors
BR112022009390A2 (pt) 2019-11-14 2022-08-09 Amgen Inc Síntese melhorada de composto inibidor de kras g12c
TW202140011A (zh) 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2抑制劑給藥和治療癌症的方法
WO2021224234A1 (en) 2020-05-04 2021-11-11 Helmholtz-Zentrum für Infektionsforschung GmbH Antiviral use of cilengitide
US11690915B2 (en) 2020-09-15 2023-07-04 Revolution Medicines, Inc. Ras inhibitors
CA3208998A1 (en) 2021-01-22 2022-07-28 Steven Kerrigan Treatment of coronavirus
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren

Also Published As

Publication number Publication date
DE19534177A1 (de) 1997-03-20
PL185125B1 (pl) 2003-02-28
RU2157379C2 (ru) 2000-10-10
HU224614B1 (hu) 2005-11-28
JP2007186525A (ja) 2007-07-26
NO963853L (no) 1997-03-17
MX9604100A (es) 1997-08-30
EP0770622B1 (de) 2000-02-02
DE59604363D1 (de) 2000-03-09
CN1203090C (zh) 2005-05-25
ATE189461T1 (de) 2000-02-15
HUP9602507A3 (en) 1998-01-28
JPH09132593A (ja) 1997-05-20
JP4116062B2 (ja) 2008-07-09
EP0770622A2 (de) 1997-05-02
BR9603751A (pt) 1998-06-02
ID18770A (id) 1998-05-07
NO963853D0 (no) 1996-09-13
HU9602507D0 (en) 1996-11-28
ES2144179T3 (es) 2000-06-01
AU717574B2 (en) 2000-03-30
EP0770622A3 (de) 1997-07-02
KR100438244B1 (ko) 2004-08-25
NO316946B1 (no) 2004-07-05
CZ286713B6 (en) 2000-06-14
CO4750841A1 (es) 1999-03-31
CA2185489A1 (en) 1997-03-16
DK0770622T3 (da) 2000-07-03
PT770622E (pt) 2000-07-31
AR003574A1 (es) 1998-08-05
AU6558096A (en) 1997-03-20
SK282391B6 (sk) 2002-01-07
TR199600716A3 (uk) 1997-04-22
GR3033293T3 (en) 2000-09-29
PL316071A1 (en) 1997-03-17
ZA967768B (en) 1997-04-07
TW517064B (en) 2003-01-11
HUP9602507A2 (en) 1997-08-28
US6001961A (en) 1999-12-14
SK116796A3 (en) 2001-05-10
CA2185489C (en) 2007-05-08
CN1149588A (zh) 1997-05-14
TR199600716A2 (tr) 1997-04-22
JP4115550B2 (ja) 2008-07-09
CZ264396A3 (en) 1997-04-16
SI0770622T1 (en) 2000-08-31
KR970015598A (ko) 1997-04-28
JP2007016042A (ja) 2007-01-25

Similar Documents

Publication Publication Date Title
UA49799C2 (uk) Циклопептиди, спосіб їх одержання, фармацевтична композиція, що їх містить, спосіб її одержання, спосіб боротьби з захворюваннями, спосіб одержання іммобілізованих лігандів
GEP19991704B (en) Carbon Derivatives, Method for Its Production, Compositions Based Thereon
AU649421B2 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
DE69622992D1 (de) Substituierte heterocyclische verbindungen, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
GB2364304A (en) Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
RU95108590A (ru) Производные имидазола
FR2670488B1 (fr) Composition pharmaceutique contenant une forme physique particuliere d'un amide heterocyclique et son procede de preparation.
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
GEP20032897B (en) Epothilone Derivatives
EE200000318A (et) Uudsed ühendid
BR9100016A (pt) Composto,isotopo radioativo do mesmo,composicao farmaceutica,metodo de tratamento ou prevencao de estados de mamiferos
FI893520A (fi) Menetelmä intravenoosisen farmaseuttisen koostumuksen valmistamiseksi
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
PL314187A1 (en) Novel derivatives of pyrazine carboxamide, method of obtaining them and their application in pharmaceutical composition
ATE534656T1 (de) Neue oligosaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE3680877D1 (de) Thiazolverbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
IL117824A (en) Pharmaceutical compositions containing 2-aryl-imidazol¬1,2-a¾pyridine-3-acetamide derivatives for treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia
ATE205480T1 (de) 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
HUT66682A (en) Process for the preparation of l-5-(2-acetoxy-propionylamino)-2,4,6,-triido-isophtalic acid dichloride
HUP9602640A2 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
HU9202358D0 (en) Imidazo(2,1-b)benzothiazole-3-acetamide derivatives, method for producing them and pharmaceutical preparatives containing said components as active agents
DE3767894D1 (de) 1,2-dithiol-3-thion-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung.
MY113230A (en) Process for the preparation of 4,10-diacetoxy-2(alpha)- benzoyloxy-5(beta),20-epoxy-1,7(beta)-dihydroxy-9-oxo-tax-11-en- 13(alpha)-yl(2r,3s)-3-benzoylamino-2-hydroxy-3-phenylpropionate trihydrate
DE3583780D1 (de) 2,3-dihydro-1h-inden-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.